Quick Facts
FONT-SIZE Plus   Neg
Share SHARE

FDA Approves Teva Pharma's NDA For Quartette Contraceptives - Quick Facts

Teva Pharmaceutical Industries Ltd. (TEVA: Quote) announced the FDA has approved Quartette tablets for the prevention of pregnancy. The approval was based on a development program that included results from Phase I, Phase II and Phase III clinical trials. The Phase III clinical trial, which involved more than 3,000 women, found that Quartette was 97 percent effective at preventing pregnancy, the company said.

Quartette features a 91-day oral regimen, whereby the dose of estrogen increases at three distinct points over the first 84 days and the amount of progestin remains consistent; this is followed by seven days of 10 mcg of ethinyl estradiol.

Click here to receive FREE breaking news email alerts for Teva Pharmaceutical Industries Limited and others in your portfolio

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Quick Facts

Editors Pick
Pro-democracy demonstrations in Hong Kong demanding greater electoral reform entered the sixth day on Wednesday, which also marks China's 65th National Day. Thousands of protesters continue to occupy parts of downtown Hong Kong vowing not to leave until they achieve their goals. They want China... Employment in the U.S. private sector increased by more than expected in the month of September, according to a report released by payroll processor ADP on Wednesday, with employment rising by more than 200,000 jobs for the sixth straight month. After ending each of the two previous sessions modestly lower, stocks may see some further downside in early trading on Wednesday. The major index futures are currently pointing to a moderately lower open for the markets, with the Dow futures down by 34 points.
comments powered by Disqus
FREE Newsletters, Analysis & Alerts

 

Stay informed with our FREE daily Newsletters and real-time breaking News Alerts. Sign up to receive the latest information on business news, health, technology, biotech, market analysis, currency trading and more.